The FDA approved cemiplimab-rwlc (Libtayo) for treatment of locally advanced, or metastatic, cutaneous squamous cell carcinoma (CSCC). This is the first drug treatment approved for advanced CSCC, the second most common cancer in the U.S. Please see the FDA website for more information.
Recent Posts
- Tackling Antimicrobial Resistance: How to fight back against the rise in tough cases
- The ‘Forever Chemicals’ Crisis: What Healthcare Providers Need to Know About PFAS
- Top Challenges Faced by Emergency Medicine Residents and How to Overcome Them
- Dry January: Exploring the Health Benefits of Reducing Alcohol Intake
- Top Winter Wellness Tips for Healthcare Providers and Patients